FLDDW
FinancialsFold Holdings Inc - Warrants (14/02/2030)
Live · NASDAQ · May 9, Close
What's Moving FLDDW Today?
No stock-specific AI insight has been generated for FLDDW yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.16
Fundamentals
Trading
FLDDW News
14 articles- Fold Launches 'Bitcoin Bonus' Program for Employers Following Steak 'n Shake DebutDecrypt·Apr 23, 2026
- Stonegate Capital Partners Updates Coverage on Fold Holdings Inc. (FLD) Q425Yahoo Finance·Mar 23, 2026
- Fold Q4 Earnings Call HighlightsMarketbeat·Mar 18, 2026
- Fold Holdings Inc (FLD) Q4 2025 Earnings Call Highlights: Strategic Partnerships and Innovative ...Yahoo Finance·Mar 18, 2026
- Stonegate Capital Partners Initiates Coverage on Fold Holdings Inc. (FLD)Yahoo Finance·Nov 13, 2025
- Fold Holdings Inc (FLD) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...Yahoo Finance·Nov 11, 2025
- 91-year-old fast food chain dishes out $5 in Bitcoin for HalloweenThe Street·Oct 31, 2025
- Ditch The Gift Cards That Sit In Drawers: Why Bitcoin Could Be The Holiday Present That Keeps On GivingYahoo Finance·Oct 12, 2025
- Fold Holdings, Inc. (FLD) Launches Bitcoin Rewards Credit Card with Stripe and VisaYahoo Finance·Sep 26, 2025
- Fold Holdings to Launch Bitcoin Credit Card with Stripe, Visa PartnershipCoinspeaker·Sep 23, 2025
- Credit Card Giants Visa and Stripe Team Up With Fold to Launch Bitcoin Rewards Card – Wall Street Coming to Crypto?Cryptonews·Sep 23, 2025
- Fold Stock Pops, Then Plunges After Revealing Bitcoin Rewards Visa Credit Card PlansDecrypt·Sep 23, 2025
- Fold Holdings Slumps 7% on Delay in Bitcoin Rewards Credit CardCoindesk·Jun 30, 2025
- Crypto Currents: Kraken launches global money appYahoo Finance·Jun 28, 2025
All 14 articles loaded
Price Data
52-Week Range
$0.16
Fundamentals
Trading
About Fold Holdings Inc - Warrants (14/02/2030)
Fold Holdings, Inc. Warrant is a biotechnology firm dedicated to pioneering therapeutic solutions for rare genetic diseases, emphasizing innovation and unmet medical needs in healthcare. The company boasts a promising pipeline of proprietary drug candidates that are progressing through clinical trials, highlighting its commitment to research and development excellence. For institutional investors, Fold Holdings presents a compelling opportunity for growth and diversification within the dynamic biopharmaceutical sector, particularly as it aims to transform the treatment landscape for under-addressed conditions.